{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:52:21Z","timestamp":1791460341579,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.yrtph.2026.106188","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:02:19Z","timestamp":1785340939000},"page":"106188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Utilization of New Approach Methodologies (NAMs) in regulatory submissions for medicated cosmetics in Japan"],"prefix":"10.1016","volume":"172","author":[{"given":"Masako","family":"Sekiguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Hatamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106188_bib1","article-title":"Regulation (EC) no 1223\/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products","volume":"342","year":"2009","journal-title":"Off. J. Eur. Union L"},{"key":"10.1016\/j.yrtph.2026.106188_bib2","series-title":"Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145 of 1960, as Amended by Act No. 37 of 2025)","year":"1960"},{"key":"10.1016\/j.yrtph.2026.106188_bib3","series-title":"ICCR Integrated Strategies for Safety Assessment of Cosmetic Ingredients - NGRA Best Practice (Report for the ICCR)","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106188_bib7","series-title":"Guidance Document No. 129: Guidance Document on Using Cytotoxicity Tests to Estimate the Starting Doses for Acute Oral Systemic Toxicity Tests (OECD Series on Testing and Assessment, No. 129)","year":"2010"},{"key":"10.1016\/j.yrtph.2026.106188_bib8","series-title":"Test Guideline No. 495: Reactive Oxygen Species (ROS) Assay for Photoreactivity (OECD Guidelines for the Testing of Chemicals, Section 4)","year":"2019"},{"key":"10.1016\/j.yrtph.2026.106188_bib9","series-title":"Test Guideline No. 442D: in Vitro Skin Sensitisation (OECD Guidelines for the Testing of Chemicals, Section 4)","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106188_bib10","series-title":"Test Guideline No. 442E: in Vitro Skin Sensitisation (OECD Guidelines for the Testing of Chemicals, Section 4)","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106188_bib11","series-title":"Test Guideline No. 497: Defined Approaches for Skin Sensitization (OECD Guidelines for the Testing of Chemicals, Section 4)","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106188_bib12","series-title":"Test Guideline No. 442C: in Chemico Skin Sensitisation (OECD Guidelines for the Testing of Chemicals, Section 4)","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106188_bib6","unstructured":"OECD, n.d. OECD guidelines for the testing of chemicals, section 4: health effects. https:\/\/www.oecd.org\/en\/publications\/serials\/oecd-guidelines-for-the-testing-of-chemicals-section-4_g1gha298.html (accessed June 11, 2026)."},{"key":"10.1016\/j.yrtph.2026.106188_bib13","series-title":"Concept of New Approach Methodologies (NAMs) Use in Quasi-drug Applications (Early Consideration) (Administrative Notice, September 25, 2025)","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106188_bib14","series-title":"Promotion of the Use of Alternative Methods to Animal Testing and Jacvam in the Preparation of Approval Application Materials for quasi-drugs","year":"2011"},{"key":"10.1016\/j.yrtph.2026.106188_bib15","series-title":"Guidance on Utilizing Alternative Skin Sensitization and Phototoxicity Tests in the Safety Evaluation of Cosmetics and quasi-drugs","year":"2012"},{"key":"10.1016\/j.yrtph.2026.106188_bib16","series-title":"Guidance on Utilizing Alternative Skin Sensitization Tests (LLNA:DA\u3001LLNA:BrdU-ELISA) in the Safety Evaluation of Cosmetics and quasi-drugs","year":"2013"},{"key":"10.1016\/j.yrtph.2026.106188_bib17","series-title":"Guidance on the Bovine Corneal Opacity and Permeability Test (BCOP) Method as an Alternative to Eye Irritation Testing for the Safety Evaluation of Cosmetics and quasi-drugs","year":"2014"},{"key":"10.1016\/j.yrtph.2026.106188_bib18","series-title":"Application for Approval of Quasi-drugs, Etc","year":"2014"},{"key":"10.1016\/j.yrtph.2026.106188_bib19","series-title":"Points to Consider on Utilizing Eye Irritation Tests in the Safety Evaluation of Cosmetics and quasi-drugs (In Japanese) (Administrative Notice, February 27, 2015)","year":"2015"},{"key":"10.1016\/j.yrtph.2026.106188_bib21","series-title":"Guidance on the Isolated Chicken Eye Test (ICE) Method as an Alternative to Eye Irritation Testing for the Safety Evaluation of Cosmetics and quasi-drugs","year":"2015"},{"key":"10.1016\/j.yrtph.2026.106188_bib22","series-title":"Guidance on the Use of in Vitro Skin Permeation (Percutaneous Absorption) Tests for the Safety Evaluation of Cosmetics and quasi-drugs","year":"2016"},{"key":"10.1016\/j.yrtph.2026.106188_bib23","series-title":"Guidance on the Evaluation System Combining Multiple Alternative Methods of Skin Sensitization Testing for the Safety Evaluation of quasi-drugs and Cosmetics","year":"2018"},{"key":"10.1016\/j.yrtph.2026.106188_bib24","series-title":"Guidance on the Short Time Exposure Test (STE) Method Using Rabbit Corneal Cell Lines as an Alternative to Eye Irritation Testing in the Safety Evaluation of quasi-drugs and Cosmetics","year":"2018"},{"key":"10.1016\/j.yrtph.2026.106188_bib25","series-title":"Q&A on Documents to be Attached to Applications for Marketing Approval of quasi-drugs and Requests for Revision of Cosmetic Standards","year":"2018"},{"key":"10.1016\/j.yrtph.2026.106188_bib26","series-title":"Guidance on the Reconstructed Human Cornea-like Epithelium (Rhce) Test Method as an Alternative to Eye Irritation Testing in the Safety Evaluation of quasi-drugs and Cosmetics","year":"2019"},{"key":"10.1016\/j.yrtph.2026.106188_bib27","series-title":"Guidance on the Evaluation System Combining Multiple Safety Data for single-dose Toxicity Evaluation of quasi-drugs and Cosmetics","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106188_bib28","series-title":"Guidance on the Skin Irritation Evaluation System in the Safety Evaluation of quasi-drugs and Cosmetics","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106188_bib29","series-title":"Guidance on the Photosafety Evaluation System for quasi-drugs and Cosmetics","year":"2022"},{"key":"10.1016\/j.yrtph.2026.106188_bib20","series-title":"Guidance on the Use of Defined Approaches for Skin Sensitization in the Safety Evaluation of quasi-drugs and Cosmetics","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106188_bib31","series-title":"SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation, 12th Revision (SCCS\/1647\/22)","year":"2023"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:06:20Z","timestamp":1791457580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026001613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":28,"alternative-id":["S0273230026001613"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106188","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of New Approach Methodologies (NAMs) in regulatory submissions for medicated cosmetics in Japan","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106188"}}